A clinical case with Anti-MOG associated demyelinating disease

Relevance. Anti-MOG-associated diseases are a relatively new and poorly studied group of autoimmune demyelinating disorders. Description of clinical cases helps to expand the understanding of the pathology, its diagnosis and treatment. The relevance of the article also lies in the demonstration of diagnostic algorithms, including the use of specific markers (anti-MOG antibodies) and neuroimaging methods (MRI). Despite the growing interest in this pathology, the number of described cases remains limited.
Objective: to study a clinical case with antiMOG-associated demyelinating disease and to identify the relevance of this disease in our time.
Materials and methods: a clinical case provided in the neurological department of the Republican Clinical Hospital No. 1, Izhevsk.
Results. Upon discharge, the following diagnosis was made: "Demyelinating disease of the central nervous system with the phenotype of ZONM (myelitis with complete regression of symptoms against the background of GC therapy), anti-AQP 4(-) (anti-MOG-associated disease) in the form of mild coordination disorders, mild subcortical syndrome, optic neuritis on the right, asthenic-subdepressive syndrome."
Conclusions. Anti-MOG-associated demyelinating disease is relevant at present, positive dynamics are observed during treatment.

1. Averchenkov DM, Volik AV, Fominykh VV et al. Acute disseminatedencephalomyelitis. S.S. Korsakov Journal of Neurologyand Psychiatry. 2021;121(11):119‑128. (In Russ.)

2. Belova AN, Sheiko GE, Rakhmanova EM, Boyko AN. Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):47‑56. (In Russ.). https://doi.org/10.17116/jnevro202312311147

3. Klinicheskie rekomendatsii po zabolevaniyam spektra optikopolinevromielita. Respublika Kazakhstan, 2022 g. Protokol № 172. (In Russ.)

4. Krasnov V.S., Rudneva Yu.A., Nazarov V.D., Vladykina A.V., Lapin S.V., Zaslavskii L.G., Totolyan N.A. MOG-IgGassociated demyelinating disorder: modern concepts, issues of diagnosis and treatment. Practical medicine. 2020. Vol. 18, № 5, P. 8-15. (In Russ.). URL: https://cyberleninka.ru/article/n/mog-igg-assotsiirovannoe-demieliniziruyuschee-zabolevanie-sovremennye-predstavleniya-voprosydiagnostiki-i-lecheniya

5. Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, Joldic D, Pittock SJ, Tillema JM, Gorman M, Lassmann H, Lucchinetti CF. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020 May;139(5):875-892. Epub 2020 Feb 11. PMID: 32048003; PMCID: PMC7181560. https://doi.org/10.1007/s00401-020-02132-y